Related by context. All words. (Click for frequent words.) 80 Gleevec resistant 75 dasatinib Sprycel ® 75 imatinib Gleevec ® 74 leukemia CLL 73 sunitinib Sutent ® 72 cell lymphoma CTCL 72 T#I [002] 72 refractory chronic myeloid 72 imatinib Gleevec 72 erlotinib Tarceva ® 71 chronic myeloid leukemia CML 71 leukemia AML 71 imatinib mesylate 71 hypereosinophilic syndrome 71 CYT# potent vascular disrupting 71 leukemia CML 71 myelofibrosis polycythemia vera 71 dasatinib Sprycel 71 chronic lymphocytic leukemia CLL 71 gastrointestinal stromal tumors GIST 70 pan HDAC inhibitor 70 metastatic malignant 70 recurrent glioblastoma multiforme 70 dasatinib 70 metastatic renal cell carcinoma 70 K ras mutations 70 gastrointestinal stromal tumor GIST 70 gefitinib Iressa 70 PEGylated Fab fragment 70 chronic eosinophilic leukemia 70 nilotinib 70 nilotinib Tasigna ® 70 T#I mutant 70 chronic myelogenous leukemia CML 70 cetuximab Erbitux ® 70 systemic anaplastic large 69 idarubicin 69 cetuximab Erbitux R 69 alefacept 69 Omacetaxine mepesuccinate 69 bevacizumab Avastin ® 69 Ph + ALL 69 cutaneous T 69 ara C 69 alkylating agent 69 imatinib therapy 69 adriamycin 69 relapsed refractory 69 vinca alkaloid 69 complement inhibitor eculizumab 69 pegylated liposomal doxorubicin 69 ceftazidime 69 Diffuse Large B 68 refractory cutaneous T 68 Ph + acute lymphoblastic 68 advanced metastatic renal 68 familial amyloidotic polyneuropathy FAP 68 SPRYCEL ® 68 mapatumumab 68 receptor tyrosine kinase inhibitor 68 bevacizumab Avastin R 68 chlorambucil 68 myelodysplastic myeloproliferative diseases 68 bortezomib Velcade 68 refractory chronic lymphocytic 68 selective modulator 68 T#I mutation 68 Myelofibrosis 68 CML CP 68 Dasatinib 68 Epratuzumab 68 chronic myeloid 68 Cutaneous T 68 Pharmacokinetics PK 68 thalidomide Thalomid 68 tigecycline 68 essential thrombocythemia 68 pharmacokinetic interactions 68 Bosutinib 67 liposomal formulation 67 Pegasys ® 67 cisplatin resistant 67 ritonavir boosted 67 Nilotinib 67 daunorubicin 67 EGFR inhibitors 67 imatinib resistance 67 Myelodysplastic Syndrome MDS 67 anti leukemic 67 gemcitabine Gemzar ® 67 metastatic GIST 67 heavily pretreated 67 refractory CML 67 Gleevec imatinib mesylate 67 fosbretabulin 67 papillary renal cell carcinoma 67 MAGE A3 ASCI 67 cisplatin gemcitabine 67 Known hypersensitivity 67 Leukemias 67 CDK inhibitor 67 vinorelbine 67 CHOP chemotherapy 67 sorafenib Nexavar 67 atypical hemolytic uremic syndrome 67 gastrointestinal stromal tumor 67 PKC# 67 azacytidine 67 erlotinib Tarceva 67 relapsed refractory multiple myeloma 67 epithelial tumors 67 myeloid 67 imatinib 67 lenalidomide dexamethasone 67 mycosis fungoides 67 nucleoside analogues 67 novel VDA molecule 67 temsirolimus Torisel ® 67 decitabine 67 relapsed MM 67 HDACi 67 hypoxia inducible factor 67 nilotinib Tasigna 67 AAG geldanamycin analog 67 Xanafide 67 trabectedin 67 Vidaza ® 67 gemcitabine Gemzar 66 alvespimycin 66 Pemetrexed 66 colon carcinoma 66 EGFR HER2 66 factor TNF 66 tyrosine kinase inhibitors TKIs 66 bleomycin 66 lymphoid malignancies 66 5 FU leucovorin 66 demonstrated antitumor activity 66 basal cell carcinoma BCC 66 ribavirin RBV 66 INCB# [003] 66 Traficet EN 66 docetaxel Taxotere ® 66 HGS ETR2 66 DMARDS 66 PEGylated anti 66 Voreloxin 66 EGFR tyrosine kinase inhibitor 66 refractory NSCLC 66 mRCC 66 pomalidomide 66 tyrosine kinase inhibitors 66 oral prodrug 66 atypical Hemolytic Uremic Syndrome 66 Fludarabine 66 metastatic neuroendocrine tumors 66 androgen independent 66 vapreotide acetate 66 receptor inhibitor 66 galiximab 66 vWF 66 YONDELIS 66 visilizumab 66 xenograft models 66 Kit CD# positive 66 ZOLINZA 66 EGFR tyrosine kinase inhibitors 66 gastrointestinal stromal tumors GISTs 66 Omacetaxine 66 liposomal doxorubicin 66 HLA DR2 66 R Saizen R 66 mycophenolate mofetil 66 stage IIIB 66 caspofungin 66 haematologic 66 cutaneous T cell 66 Navelbine ® 66 D aspartate NMDA receptor 66 Chronic Myeloid Leukemia CML 66 interferon IFN 66 TKIs 66 pancreatic adenocarcinoma 66 mTOR mammalian target 66 hA# 66 FOLFIRI 66 Vidaza azacitidine 66 proteasome inhibitor 66 Doxil ® 66 orally administered inhibitor 65 p# mitogen activated 65 mTOR inhibitor 65 Epidermal Growth Factor Receptor 65 MGd 65 Darinaparsin 65 Bortezomib 65 ovarian carcinoma 65 invasive candidiasis 65 dexamethasone Decadron 65 docetaxel chemotherapy 65 small lymphocytic lymphoma 65 subcutaneously administered 65 IAP inhibitor 65 Ceflatonin 65 myeloproliferative diseases 65 FUSILEV enhances 65 targeting CD# 65 metastatic castration resistant 65 systemic fungal infections 65 isoproterenol 65 conventional DMARDs 65 histone deacetylase inhibitor 65 Ribavirin causes 65 FOLFOX chemotherapy 65 autoantibody positive 65 S/GSK# 65 cyclophosphamide methotrexate 65 CANCIDAS 65 interferon alfa 2b 65 huN# DM1 65 5 HT6 receptor 65 TNF Tumor Necrosis Factor 65 Vorinostat 65 alkylating 65 Aplidin R 65 Chronic Myeloid Leukemia 65 evaluating tivozanib 65 luteinizing hormone releasing 65 Complicated Skin 65 essential thrombocythemia ET 65 refractory ovarian cancer 65 Tarceva TM 65 irinotecan doxorubicin oxaliplatin paclitaxel 65 kidney urologic 65 Relapsed Refractory 65 azacitidine 65 sorafenib Nexavar ® 65 lenalidomide Revlimid R 65 Luteinizing Hormone Releasing Hormone 65 oral JAK1 65 biliary tract cancer 65 tumors GIST 65 humanized anti 65 anti angiogenic agents 65 sarcomatoid 65 standard chemotherapy regimen 65 Taxol ® 65 pancreatic neuroendocrine tumors 65 Enzastaurin 65 ALK inhibitor 65 HER2 positive metastatic breast 65 bendamustine 65 Platinol 65 NS5B polymerase 65 efalizumab 65 prostate carcinoma 65 DFMO 65 premalignant 65 oxaliplatin Eloxatin 65 refractory AML 65 EGFr 65 Interferon alpha 65 denileukin diftitox 65 castration resistant prostate cancer 65 Etanercept 65 5 fluorouracil leucovorin 65 selective antagonist 65 Navelbine 65 lysosomal storage disease 65 sunitinib Sutent 65 hepatoma 65 CD4 monoclonal antibody 65 Akt activation 65 Albuferon TM 65 tumor xenograft models 64 Refractory Hodgkin Lymphoma 64 posaconazole 64 crizotinib PF # 64 interferon alfa 64 fludarabine 64 paclitaxel Taxol 64 gemcitabine carboplatin 64 TELCYTA 64 flavopiridol 64 Sudhir Agrawal D.Phil 64 KRAS wild 64 sodium glucose cotransporter 64 HER2 overexpression 64 uric acid lowering 64 V#F mutation 64 echinocandin 64 BCR ABL 64 gastrointestinal stromal tumors 64 Amrubicin 64 demethylating agent 64 pentamidine 64 NR2B selective 64 mTOR inhibitors 64 estramustine 64 sulfasalazine 64 somatostatin analogue 64 metastatic colorectal 64 histologies 64 Irinotecan 64 sorafenib tablets 64 IFN α 64 Lenalidomide 64 DMARD 64 chemotherapeutic drug 64 pertuzumab 64 colorectal carcinoma 64 interleukin IL -# 64 biologic therapy 64 panitumumab Vectibix 64 CYP#A# substrate 64 Aplidin 64 FLT3 64 Ziprasidone 64 Gleevec imatinib 64 Romiplostim 64 GW# [003] 64 Fludara ® 64 serologically active systemic lupus 64 EGFR antibodies 64 beta 1a 64 cyclophosphamide Cytoxan 64 Zolinza 64 ERBB2 64 paclitaxel cisplatin 64 sunitinib malate 64 fulvestrant 64 B CLL 64 HGS ETR1 64 tyrosine kinase inhibitor TKI 64 dacarbazine 64 ENMD # 64 Imatinib 64 VAPRISOL 64 syngeneic 64 cilengitide 64 refractory multiple myeloma 64 multiple myeloma MM 64 nucleoside analog 64 purpura ITP 64 azoles 64 refractory gout 64 histone deacetylase HDAC inhibitor 64 protease inhibitor PI 64 melphalan prednisone 64 polyglutamate 64 Cloretazine 64 LHRH receptor positive 64 2 methoxyestradiol 64 Toxicities 64 neurological manifestations 64 Kahalalide F 64 Peginterferon alfa 2b 64 Aflibercept 64 N methyl 64 immunomodulatory therapy 64 Methylnaltrexone 64 Vidaza R 64 HCV protease 64 anthracyclines taxanes 64 alfa 2a 64 metastatic RCC 64 Bcr Abl mutations 64 leukemia ALL 64 risperidone Risperdal 64 haematopoietic 64 superficial bladder cancer 64 pancreatic NET 64 bortezomib 64 castrate resistant prostate cancer 64 somatostatin analog 64 CsA 64 Ranolazine 64 refractory acute myeloid 64 uricase 64 JAK2 V#F 64 mCRC patients 64 Teriflunomide 64 pheochromocytoma 64 trastuzumab Herceptin ® 64 pediatric Crohn disease 64 etoposide 64 cis retinoic acid 64 Multiple Myeloma MM 64 phase IIb clinical 64 Noxafil 64 Degarelix 64 docetaxel Taxotere R 64 follicular lymphoma FL 64 Trastuzumab 64 doxorubicin Adriamycin 64 endothelin receptor 64 ALB # 64 Genentech Rituxan 64 polycythemia vera PV 64 ganetespib 64 metastatic malignant melanoma 64 myeloproliferative disorders 64 recurrent genital herpes 64 Sezary syndrome 64 polymerase inhibitor 64 Annamycin 64 BRAF mutations 64 dopamine D2 64 pegylated 64 prostate cancer mCRPC 64 cytostatic 63 HuMax CD4 63 effector function 63 paricalcitol 63 Mg Usa 63 quetiapine Seroquel 63 ponatinib 63 Rituxan rituximab 63 indolent NHL 63 BARACLUDE ® 63 M2 subunit 63 disease modifying antirheumatic 63 mucinous 63 replicon 63 lymphoma CTCL 63 HCV genotypes 63 Elotuzumab 63 imipenem 63 HGS ETR1 mapatumumab 63 systemic lupus erythematosus SLE 63 hematological malignancy 63 EGF receptor 63 mGluR5 NAM 63 oblimersen 63 haematological malignancies 63 trastuzumab Herceptin R 63 esophageal candidiasis 63 irinotecan containing 63 Fludara 63 irreversible inhibitor 63 CLL SLL 63 metaglidasen 63 antibody MAb 63 interferon gamma 1b 63 IFN beta 63 Blinatumomab 63 pharmacologically active isomer 63 pegylated interferon alfa 2a 63 Fulvestrant 63 cell lymphoma ALCL 63 SCCHN 63 Hodgkin lymphoma NHL 63 Personalized Immunotherapy 63 Hsp# Inhibitor 63 Factor Receptor 63 radiation sensitizer 63 papillary RCC 63 6 mercaptopurine 63 trans retinoic acid 63 thrombin receptor 63 KRAS mutations occur 63 weekly subcutaneous injections 63 recurrent glioblastoma 63 heavily pretreated patients 63 riociguat 63 chimeric monoclonal antibody 63 potent antiviral 63 IMiDs ® compound 63 resectable 63 HuLuc# 63 microtubule targeting 63 vandetanib 63 IL 1ß 63 progressive PsA 63 Tolvaptan 63 AVASTIN 63 glioblastoma multiforme GBM 63 MabCampath 63 tumor lysis syndrome 63 superficial basal cell carcinoma 63 relapsed ovarian cancer 63 Decitabine 63 vascular disrupting agents 63 antimetabolite 63 mutated KRAS 63 FEMALES SHOULD BE ADVISED 63 Virulizin ® 63 Soft Tissue Sarcoma 63 PegIFN 63 nucleoside analogs 63 pegylated interferons 63 Rituximab 63 CYP#A# CYP#D# 63 non alcoholic steatohepatitis 63 PNP inhibitor 63 Zorbtive TM 63 EGFR TKI 63 Akt inhibitor 63 K ras 63 adalimumab Humira 63 INTEGRILIN R 63 Seliciclib 63 biologic DMARD 63 TO AVOID PREGNANCY WHILE 63 targeted antifolate 63 Gefitinib 63 rituximab Rituxan 63 Paraplatin ® carboplatin 63 haloperidol Haldol 63 myeloproliferative 63 systemic lupus erythematosus 63 Paraplatin ® 63 Abatacept 63 subependymal giant cell 63 Bcr Abl T#I mutation 63 infliximab 63 tiuxetan 63 3TC lamivudine Epivir 63 plus prednisone prednisolone 63 tanespimycin 63 cMET 63 primary hypercholesterolemia 63 Apoptone 63 carboplatin paclitaxel 63 relapsed multiple myeloma 63 ifosfamide 63 KRAS mutations 63 4mg/kg 63 ON #.Na 63 itraconazole 63 PI3K Akt 63 human tumor xenografts 63 PTPN# 63 TTR gene 63 MEK inhibitors 63 BCR ABL mutations 63 cell carcinoma RCC 63 tyrosine kinase inhibitor 63 stage IIIb IV 63 alpha interferons 63 ACTEMRA TM 63 Chronic Lymphocytic Leukemia CLL 63 pegylated interferon alpha 63 myelodysplastic syndrome MDS 63 PRTX 63 ERK1 2 63 5alpha reductase 63 intravesical instillation 63 HLA DR4 immune 63 erythropoietic 63 immunomodulator 63 hypermethylated 63 FLT3 ITD 63 nucleoside 63 Janus Kinase 63 vitro cytotoxicity 63 PDGFR 63 alkylating agents 63 doxorubicin cyclophosphamide 63 MYLOTARG 63 acute myeloid 63 humanised monoclonal antibody 63 Bezielle 63 UGT#A# 63 Tumor Necrosis Factor 63 myeloablative 63 TRAIL induced apoptosis 63 Cell Lymphoma 63 Temsirolimus 63 Cannabinor 63 itraconazole Sporanox 63 #HT#A 63 cytogenetic responses 63 ADP receptor antagonist 63 Tyrosine Kinase Inhibitor 63 dacarbazine DTIC 63 VEGF inhibitors 63 Imatinib mesylate 63 voriconazole 63 elotuzumab 63 TOP2A 63 Acute Myeloid Leukemia AML 63 follicular lymphomas 63 IFN alpha 63 ELOXATIN 63 vWD 63 HBeAg positive 63 constitutively active 63 EGFR mutation positive 63 γ secretase 63 DLBCL 63 bortezomib Velcade R 63 lamivudine 3TC 63 lupus nephritis 63 dextromethorphan quinidine 63 Flu Cy 63 immunostimulatory 63 Systemic lupus erythematosus SLE 63 ABSSSI 63 bexarotene 63 tocilizumab 63 JAK2 enzyme 63 BRAF inhibitor 63 efaproxiral 63 refractory CLL 63 Chronic lymphocytic leukemia 63 Hematologic 63 refractory CTCL 63 TRAIL R2 63 VELCADE melphalan 63 HBeAg negative 63 CA4P 63 unresectable 63 Vaprisol 63 xanthine oxidase inhibitor 63 intravenous belinostat 63 promoter methylation 63 fluvastatin 62 colony stimulating factor 62 immune modulating 62 Dapagliflozin 62 relapsing multiple sclerosis 62 histone deacetylases 62 calcineurin inhibitors 62 Adalimumab 62 APTIVUS r 62 5 HT1A receptor 62 reteplase 62 pharmacodynamic PD 62 OHR/AVR# 62 antiproliferative effects 62 romidepsin 62 Peginterferon Alfa 2a 62 parthenolide 62 acute leukemias 62 paclitaxel Taxol ® 62 IMiDs R 62 protein tyrosine phosphatase 1B 62 pan histone deacetylase 62 virus HCV protease inhibitor 62 pathophysiological effects 62 KRAS mutant 62 Randomized Phase 62 eosinophilic asthma 62 micafungin 62 cidofovir 62 Antitumor Activity 62 Janus kinase 62 mitogen activated protein kinase 62 administered concomitantly 62 cediranib 62 hepatocellular carcinoma HCC 62 Myeloid 62 TNF antagonist therapies 62 TNFalpha 62 GRASPA ® 62 situ CIS 62 AZT zidovudine Retrovir 62 amrubicin 62 BRAF V#E 62 Romidepsin 62 CD# antibody [001] 62 follicular NHL 62 acute humoral rejection 62 non nucleoside inhibitor 62 lamivudine resistant 62 LymphoStat B belimumab 62 K RAS 62 Lenocta 62 cytokeratin 62 Anthracycline 62 ISTODAX ® 62 hypomethylating agents 62 hypercalcemia 62 temozolomide 62 generation purine nucleoside 62 meropenem 62 refractory Hodgkin lymphoma 62 DMARDs 62 NRTI resistance 62 olmesartan 62 CD# monoclonal antibody 62 castration resistant 62 pamidronate 62 HBeAg positive patients 62 5 Fluorouracil 62 severe neutropenia 62 acute GvHD 62 small molecule Hedgehog 62 DAVANAT 62 Erlotinib 62 BRAF V#E mutation 62 idiopathic myelofibrosis 62 liposomal amphotericin B 62 HNSCC 62 synthase TS 62 Aurora Kinase 62 Taxotere ® 62 immunomodulation 62 Talactoferrin 62 p# biomarkers 62 Antiviral Activity 62 imatinib mesylate Gleevec 62 androgen receptor AR 62 fallopian tube cancers 62 Pegylated 62 nab paclitaxel 62 Aurora kinase 62 proto oncogene 62 anterior uveitis 62 NF kB pathway 62 tumorigenicity 62 Solid Tumors 62 certolizumab 62 TKI therapy 62 selective agonist 62 basiliximab 62 AMN# [001] 62 sunitinib 62 mononuclear 62 Rindopepimut 62 antiestrogen 62 hepatocellular carcinomas 62 epithelioid 62 brand ciclesonide HFA 62 Mutational 62 antitumor effect 62 non metastatic resectable 62 neoplastic 62 leukotriene receptor antagonist 62 potent inhibition 62 gemcitabine cisplatin 62 ceftriaxone 62 CBLC# 62 Pathway Inhibitor 62 XL# inhibits 62 receptor blocker 62 veltuzumab 62 systemic juvenile idiopathic 62 antitumour activity 62 EGFR TKIs 62 Upregulation 62 amprenavir 62 Crohn disease CD 62 Chronic Myelogenous Leukemia 62 plus gemcitabine 62 platinum refractory 62 Lamotrigine 62 Adjuvant chemotherapy 62 recombinant tissue plasminogen 62 relapsed leukemia 62 nutlin 3a 62 NAGS deficiency 62 selectively inhibited 62 HepG2 cells 62 amphotericin B 62 castrate resistant 62 temsirolimus 62 histological subtype 62 serine threonine 62 immunocompetent patients 62 rhIL 7 62 PI3K inhibitor 62 Granulocyte Colony Stimulating Factor 62 pimozide 62 Azacitidine 62 echinocandins 62 glatiramer acetate 62 VFEND 62 angiotensin converting enzyme inhibitors 62 Maribavir 62 cytarabine daunorubicin 62 recurrent NSCLC 62 Naive Patients 62 Systemic lupus erythematosus 62 lapatinib Tykerb 62 Lacosamide 62 SCIg 62 Atypical Hemolytic Uremic Syndrome 62 LEUKINE 62 peginterferon alfa 62 TNF antagonists 62 pancreatic carcinoma 62 EGFR mutations 62 IMA# 62 Estrogen Receptor 62 prostate cancer CaP 62 tenofovir Viread 62 CIMZIA TM 62 Sipuleucel T 62 Tyrima 62 elacytarabine 62 breast carcinomas 62 anthracycline taxane 62 erythematosus SLE 62 vemurafenib 62 antiangiogenic therapy 62 milatuzumab 62 GNAQ 62 selective inhibitor 62 5HT 62 selective inhibition 62 interferon γ 62 fluoropyrimidine 62 Ceftaroline 62 DOXIL 62 c MET 62 antiarrhythmic 62 low dose cytarabine 62 saline placebo 62 lytic 62 Immunohistochemical analysis 62 Vincristine 62 acadesine 62 5 HT3 receptor 62 baminercept 62 Letairis ambrisentan 62 acute promyelocytic leukemia APL 62 mitomycin 62 Orally administered 62 noninferior 62 Relapsed 62 Leukine ® 62 chemokine receptor 62 Philadelphia Chromosome Positive 62 favorable pharmacokinetic profile 62 rituximab 62 CD# expressing 62 CYP #D# 62 C1 INH deficiency 62 Yondelis ® 62 cell malignancies 62 murine model 62 squamous cell lung cancer 62 PDGF receptor 62 methicillin susceptible Staphylococcus aureus 62 E. faecalis 62 tipranavir ritonavir 62 potent antiproliferative 62 TELINTRA 62 Pafuramidine 62 Vidofludimus 62 FK# 62 HLA DRB1 * 62 hTERT 62 unstable angina UA 62 TNF receptor 62 inducible nitric oxide synthase 62 interferon alfa 2a 62 PsA 62 Platinol ® cisplatin 62 Ceflatonin R 62 R lenalidomide 62 iobenguane 62 Sym# 62 TNF antagonist 62 FOLPI 62 immunomodulatory 62 JAK1 62 BMS # 62 intravenous dosing 62 splenectomized 62 non metastatic osteosarcoma 62 dopamine receptor agonist 62 relapsed acute myelogenous 62 Carfilzomib 62 Roche Pegasys 62 platelet inhibitor 62 corticosteroid therapy 62 Bendamustine 62 piperacillin tazobactam 62 reversible inhibitors 62 lymphoid cells 62 double blinded placebo 62 antiangiogenic agent 62 HSP# inhibitor 62 COX2 62 telaprevir dosed 62 Castration Resistant Prostate Cancer 62 paraganglioma 62 levetiracetam Keppra 62 pharmacokinetic properties 62 cytokine signaling 62 mda 7 62 HCV replicon 62 HCV NS5B polymerase 61 dose escalation phase 61 dyskinesia PD LID 61 monoclonal anti 61 inhibitor RG# 61 pulmonary hypertension PH 61 chemo immunotherapy 61 chemotherapeutic regimen 61 TTR amyloidosis 61 Certolizumab pegol 61 MTHFR 61 Liposomal 61 Talabostat 61 SSc 61 oral rivaroxaban 61 chronic immune thrombocytopenic 61 pegylated interferon alfa 61 orally bioavailable 61 ganciclovir 61 IFNa 61 HGS# 61 telomerase reverse transcriptase 61 amphotericin 61 EGFR mutant 61 CD#c 61 anti angiogenic agent 61 cefotaxime 61 EGFR TK 61 refractory metastatic 61 Glufosfamide 61 cancer mCRC 61 alpha 2a 61 HBeAg negative patients 61 FGFR1 61 enzastaurin 61 colorectal liver metastases 61 Dementia Related Psychosis 61 BAL# [002] 61 multikinase inhibitor 61 ® lenalidomide 61 metastatic hormone refractory 61 cytotoxin 61 synovial fibroblasts 61 recurrent glioma 61 IGF IR 61 GHRH 61 XYOTAX TM 61 microglial activation 61 TACE 61 Camptosar ® 61 metastatic gastric 61 huC# DM4 61 abacavir lamivudine 61 ERK signaling 61 FOLFOX6 chemotherapy regimen 61 carcinoid tumors 61 HMG CoA reductase inhibitor 61 INVANZ 61 Folfox 61 Combination therapy 61 AEG# 61 IMiDs ® 61 amoxicillin clavulanate 61 CCyR 61 Meets Primary Endpoint 61 aflibercept VEGF Trap 61 ABCB1 61 polymerase inhibitors 61 pegylated alpha interferon 61 FOLOTYN ® 61 genotypic resistance 61 carcinoid 61 panobinostat 61 NXL# 61 MMP2 61 bullous 61 Pioglitazone 61 RoACTEMRA 61 HCV SPRINT 61 LHRH agonist 61 Triapine 61 nucleoside analogue 61 ixabepilone 61 investigational humanized monoclonal antibody 61 ULORIC 61 activating mutations 61 verteporfin 61 sorafenib 61 Doxorubicin 61 gefitinib 61 CIMZIA R 61 Pralatrexate 61 glycopeptide 61 MEK1 61 Helicobacter pylori eradication 61 investigational monoclonal antibody 61 Aliskiren 61 Mg Uk 61 primidone 61 administered subcutaneously 61 immunocompetent 61 ZYBRESTAT fosbretabulin 61 relapsed SCLC 61 adipogenic 61 apoptotic pathway 61 squamous cell carcinoma SCC 61 angiotensin receptor 61 Quinamed 61 ribavirin therapy 61 gemcitabine 61 FOLFOX6 61 drugs DMARDs 61 IFN γ 61 chemotherapeutic agent